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Abstract
Background: Patients with primary and metastatic liver malignancies represent a highly heterogeneous patient
pool characterised by some of the shortest life expectancies amongst oncology patients. Investigation and better
understanding of liver malignancies is an emerging field which requires high-quality multidisciplinary research and
collaboration.
Methods: A study of 158 patients with primary hepatic carcinomas and secondary liver metastases, altogether
15 cancer types of different origin, who underwent selective internal radiation therapy (SIRT) with Yttrium90 or
transarterial chemoembolisation, was undertaken in an effort to detect distinguishing features with respect to
activity profiles of both blood matrix metalloproteinase (MMP-2 and MMP-9).
Results: Noteworthy, stratification of all hepatic cancer groups with respect to MMP-2 and MMP-9 activities
revealed characteristic patterns specifically in patients with hepatic breast cancer metastases who had undergone
SIRT. In contrast to all other groups, these patients demonstrated well-consolidated profiles of both MMPs,
reflecting a common feature, namely an immediate and durable increase of their activity after the SIRT treatment.
Although the total number of patients in the breast cancer group is relatively small (15 patients), since increased
activities of MMP-2 and MMP-9 are well known prognostic factors for poor outcomes of oncologic patients, the
significance and clear group-specificity (from 15 ones investigated here) of this previously unanticipated finding
requires particular attention and further investigations. Particularly important is to determine, whether this increase
of the metalloproteinase activity was provoked by SIRT, as well as whether special selection criteria are required for
patients with breast cancer metastases to the liver who are being considered for SIRT.
Conclusions: It is recommended that a more focused, multidisciplinary and large-scaled investigations of the
possible adverse effects of SIRT in patients with advanced metastatic disease of breast cancer be undertaken, with
an appropriate patients’ stratification, set-up of the relevant patient profiles and disease modelling.
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Background
Patients with primary and metastatic liver malignancies
represent a highly heterogeneous patient pool charac-
terised by some of the shortest life expectancies amongst
oncology patients. Liver cancer is the sixth most common
cancer worldwide, with more than 782,000 new cases
diagnosed in 2012 (6 % of the total) [1]. Primary hepatic
tumours frequently originate from well-defined local trig-
gers such as organ-specific chronic inflammation, hepatitis
and/or liver cirrhosis. Secondary, or metastatic, liver ma-
lignancies are even more common than primary tumours,
presenting a heterogeneous and complex clinical picture.
The most common sites of primary tumour are breast,
lung, and colorectal cancer [2]. Some authors have re-
ported hepatic metastases in as many as 40 to 50 % of
adult patients with extrahepatic primary tumours.
The approach to diagnosis, prognosis, and treatment is
dependent upon the localisation and determination of
the biological activity of the original tumour, with wide
variation in expected response of liver metastases to
treatment. For certain tumours, such as a solitary metas-
tasis to the liver from colorectal cancer, there is a
favourable survival rate following liver resection that
represents relatively simple mechanisms of a local spread
of malignant cells in an immediate neighbour-organ
within the abdominal compartment.
A completely different set of circumstances is encoun-
tered when there is systemic spread of distant metasta-
ses. The process is highly complex and requires certain
obligatory steps at the cellular and molecular level: pri-
mary tumourigenesis, local tumour-related invasion and
angiogenesis, down-regulated cell-cell adhesion within
cancerous lesions, systemic spread of cancerous infor-
mation (CNAPs, cell-free DNA/RNA, circulating tumour
cells), creation of organ/tissue specific metastatic envir-
onment, metastatic seeding, entry into dormancy, meta-
static growth provocation, and, genotype modifications
under therapy conditions frequently leading to more
aggressive phenotypes of secondary and tertiary tumours
compared to the original ones.
In particular, the above listed processes are character-
istic for liver metastases from breast cancer. Recent pub-
lications in the area demonstrate that despite improved
treatments, the prognosis for non-operable patients with
liver metastases from breast cancer metastatic disease
(BCMD) remains poor [3].
Our current study of BCMD is motivated by the fol-
lowing reasons:
1. BCMD is considered an incurable disease: there are
poor outcomes and a low life expectancy of this
patient cohort [4].
2. The liver is one of the most frequent sites of
involvement in patients with BCMD [5]. Depending
on the sub-type of breast cancer and infectious
component, the liver involvement may reach 25 % of
patients and more [6, 7].
3. In postoperative breast cancer patients liver
metastases appear earlier than other distanced
metastases [8]; a spontaneous dormancy of
metastatic breast cancer cells to the liver has been
demonstrated [9].
4. The BCMD to liver is linked to the particularly
poor outcomes: current studies with multivariate
analysis confirmed liver involvement in BCMD
as independent predictor of worse overall
survival [10].
5. The molecular background of the therapy resistance
in BCMD has not been adequately studied yet.
Stratification of patients into prognostic groups is
essential.
An extensive degradation of extracellular matrix is the
essential attribute of tumour progression and aggressive
metastatic disease. Within the protein family of prote-
ases degrading the extracellular matrix, both gelatinases
A and B—metalloproteinases MMP-2 and MMP-9,
respectively—are well known prognostic factors that,
when elevated, are indicators of poor outcomes for on-
cologic patients in general, and, in particular, promoting
liver metastases [11, 12], metastatic disease in the most
aggressive breast cancer phenotypes (such as triple-
negative breast cancer) [13] and formation specifically of
liver metastases in breast cancer [14]. Further, the pat-
terns of activities of both MMP-2 and −9 are regulated
by many molecular mechanisms applied via a cascade of
individual steps including transcription, translation, sev-
eral events of post-translational modification and, finally,
MMP-activity inhibition by TIMPs. In this comprehen-
sive situation, it is very difficult to expect a linear correl-
ation between expression rates (e.g. measured by ELISA)
and levels of activity (Zymography used in the project).
From the entire regulation cascade, the “end-products”,
namely effective activity levels of both molecular targets
have the highest relevance for biological aspects of meta-
static disease and practical clinical utility. Consequently,
the current paper is focused on specific patterns of activ-
ities of both MMP-2 and −9 in patients with primary
and metastatic liver malignancies.
Methods
Recruitment of patients with primary and secondary
hepatic carcinomas and blood sample collection
A total of 158 patients with primary and secondary hep-
atic carcinomas were recruited at the Department of
Radiology, Rheinische Friedrich-Wilhelms-University of
Bonn.
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Including criteria
– primary hepatic carcinoma
– hepatic metastases
– treatment by SIRT (Selective Internal Radiation Therapy)




– acute infections (but not chronic hepatitis)
– alcohol abuse
– genetic disorders and disorders with premature
ageing (Down Syndrome, Werner Syndrome,
Alzheimer’s disease, others)
The recruited patients were grouped according to the
primary diagnosis (original tumour), gender, and therapy
approach chosen and applied to the patient—see the
workflow presented in Fig. 1. Blood samples of all pa-
tients were taken
– 1st time prior to the intervention
– 2nd time at the day of the release from the clinic
– 3rd, 4th and 5th times during the follow-up phase.
Blood samples collection and biobanking
Blood samples (20 ml) anti-coagulated with heparin
were collected from the patients. For the current study,
blood plasma (500 μl) has been separated by short cen-
trifugation and stored at −80 °C until the zymographic
analysis were performed as described below.
For the biobanking and all follow-up analyses, circulat-
ing leukocytes were separated using Ficoll-Histopaque
gradients (Histopaque 1077, Sigma, USA) as described
previously [15]. Briefly, blood samples were diluted with
equal volumes of physiological buffer solution (PBS,
Biochrom AG, Germany). Then, 2 ml of histopaque were
placed into 10 ml sterile centrifuge tubes and 5 ml of
diluted blood samples were carefully layered onto each
histopaque gradient. Gradients were centrifuged at 475 g
and 20 °C for 15 min. The leukocytes bands were re-
moved from the interface between plasma and histopa-
que layers of each tube and collected into one 50 ml
tube. The total volume was brought to 50 ml with cold
Dulbecco’s Modified Eagle Medium (DMEM, Gibco™,
USA). The cell suspension was washed three times with
PBS and the total number of cells was determined. Cells
were finally resuspended in PBS-DMSO solution, ali-
quoted into eppendorf tubes and stored at −80 °C until
molecular profiling in circulated leukocytes might be
needed to be performed.
Zymography
For determination of gelatinase activity of MMP-2 and
MMP-9 in blood serum "Criterion™ Zymogram Gel" (Bio-
Rad, USA) were used according to the instructions of the
manufacturer. Two microliters from individual serum
samples were electrophoresed under non-reducing condi-
tions using Criterion™ Precast Gel System (Bio-Rad, USA).
After electrophoresis, each gel was incubated at room
temperature in 2 % Triton X-100 for 2 x 30 min in
order to remove the traces of sodium dodecyl sulphate,
and then incubated overnight at 37 °C in buffer
(150 mM NaCl, 50 mM Tris–HCl, pH 7.6, containing
Fig. 1 Workflow. The scheme summarises how the entire study has been designed and experimental approach performed in the patients pool
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5 mM CaCl2 and 0.02 % NaN3). Afterwards a staining
with 0.5 % Coomassie blue G-250 (Sigma, USA) was
performed for each gel. The proteolytic activity of each
gelatinase (A and B) was identified as a clear band on a
blue background according to the correspondent mo-
lecular weight of each gelatinase (A and B that corre-
sponds to the Metallproteinase-2 and −9, respectively).
Gels were dried between cellophane sheets with a
GelAir™ Drying System (Bio-Rad, USA) and then
scanned with a yellow filter using Adobe Photoshop
(Adobe System, USA) in grey-scale mode. Densitomet-
ric analysis of zymographic lysis zones at 66 and
86 kDa for gelatinases A and B respectively was per-




Patient data analysis is summarised in the Table 1.
Patient data analysis of 158 patients with primary
hepatic carcinomas and secondary metastasis revealed
following differentiations:
– for the gender: 65 females and 93 males
Cancer types: 59 Hepatocellular Carcinoma, 48 Colorectal
Cancer, 15 Breast Cancer, 10 Cholangiocellular Carcinoma,
8 Neuroendocrine Tumour, 3 Pancreatic Cancer, 3 Lung
Cancer, 2 Esophageal Cancer, 2 Ovarian Cancer, 1 Cervical
Cancer, 3 Gastric Cancer, 1 Mixed Adenoneuroendocrine
Carcinoma, 1 Urothelial Cancer, 1 Uveal Melanoma, 1
Cancer of Unknown Primary
– Therapy: 79.75 % SIRT and 20.25 % TACE
Mortality in the cohort of the patients with hepatic breast
cancer metastases
The cohort of the patients with hepatic breast cancer
metastases for 100 % was treated with the SIRT. The
mortality rates were recorded as following:
– one third part of the group died within 3 months
after the treatment
– 60 % died within 1 year.
MMP-9 patterns in blood
A. All primary and secondary hepatic carcinomas stratified
according to individual MMP-9 profiles in blood
Stratification of all 158 hepatic carcinoma patients con-
sidering individual MMP-9 profiles in blood revealed 8
key patterns as summarised in Fig. 2. In general, the
patterns’ distribution across the individual groups of
patients stratified according to the gender, cancer, and
therapy type was highly heterogeneous.
B. Cohort of the patients with hepatic breast cancer
metastases
In contrast to all other groups, the patients with hepatic
breast cancer metastases demonstrated well consolidated
MMP-9 profiles reflecting the main common feature,
namely an immediate increase and stably high level of
the MMP-9 activity after the SIRT application that
corresponds to the patterns 1A, 1C, 1D, 2B1. The four
patterns have been recorded as the characteristic for this
patient cohort.
MMP-2 patterns in blood
A. All primary and secondary hepatic carcinomas stratified
according to individual MMP-2 profiles in blood
Stratification of all 158 hepatic carcinoma patients con-
sidering individual MMP-2 profiles in blood revealed 8
key-patterns as summarised in Fig. 3. In general, the
patterns’ distribution across the individual groups of
patients stratified according to the gender, cancer and
therapy type was highly heterogeneous.
B. Cohort of the patients with hepatic breast cancer
metastases
In contrast to all other groups, but similarly to the
MMP-9 patterns, the patients with hepatic breast cancer
metastases demonstrated also well consolidated MMP-2
profiles reflecting the same main feature, namely an
increasing and stably high level of MMP-2 activity after
the SIRT application that corresponds to the patterns
2A1, 2B, 3A, 3B1. The four patterns have been registered
as the characteristic for this patient cohort. A very few
exceptions demonstrated the pattern 2D (unchanged after
the therapy); however, the initial level of the MMP-2
activity in those cases was extremely high.
Discussion
For selected patients with primary or metastatic hepatic
cancer, liver resection is felt to offer the best overall
chance of cure. Unfortunately, at the time of the diagno-
sis only 10–20 % of cases are candidates for a surgical
approach. Consequently, the overwhelming majority of
the patients with hepatic tumours are treated with stan-
dardised palliative approaches which aim at stabilising
the tumour’s growth and slowing down its metastatic ac-
tivity. The success rates of these treatments are widely
variable, resulting in survival rates that range from several
weeks to over two years following treatments. In par-
ticular, it is unclear why tumours with apparently similar
anatomic characteristics, undergoing similar treatment
regimens, lead to different individual outcomes. The mat-
ter is hardly explainable by currently available diagnostic
and prognostic tools. An approach to achieving greater
understanding of the wide variation in biologic activity
and patient-specific response to therapy utilising an
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Gender M F M F M F M F M F M F M F M F M F M F M F M F M F M F M F
No of
Cases
45 14 30 18 - 15 4 6 5 3 2 1 1 2 2 - - 2 - 1 2 1 - 1 - 1 1 - 1 -
Age (Ø) 67.98 66.79 64.73 61.22 - 55.33 65.25 61.5 55.8 60.67 52.5 50 55 57.5 57 - - 49.5 - 52 58 61 - 31 - 73 61 - 46 -
TACE
(in %)
48.89 42.86 3.33 0 - 0 0 0 0 0 0 100 100 0 0 - - 0 - 0 0 0 - 0 - 100 0 - 0 -
SIRT
(in %)












Fig. 2 MMP-9 patterns. Above constructed patterns have been monitored for activities of MMP-9 in blood serum of individual subgroups of all
hepatic carcinoma patents investigated in the current study
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Fig. 3 MMP-2 patterns. Above constructed patterns have been monitored for activities of MMP-2 in blood serum of individual subgroups of all
hepatic carcinoma patents investigated in the current study
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Information Technology framework, with respect to hepa-
tocellular cancer, has been recently proposed [16, 17].
Work is currently underway in understanding variability
in individual responses through data-mining utilising
graph theory and Bayesian inference.
In addition, variations in patient response to treatment
have motivated the authors to build a multidisciplinary
consortium to analyse the diversity of liver malignancies,
to develop multilevel studies, and to seek potential ex-
planations for discrepancies recorded for the treatment
outcomes. Accordingly, in the study presented herein,
158 patients with liver malignancies of 15 different types
of the cancer origin were treated with TACE or SIRT,
and their outcomes were analysed. A small but striking
subset of subjects, namely the patient cohort with hep-
atic breast cancer metastases treated by SIRT displayed
group-specific remarkable findings:
1. the mortality rates were high: one-third of the group
died within 3 months after the treatment and 60 %
died within 1 year;
2. in contrast to all other groups, the patients with
hepatic breast cancer metastases demonstrated well
consolidated MMP-9 and MMP-2 profiles, reflecting
a unique, common feature, namely an immediate
and permanent follow-up increase in the activity
rates of both matrix metalloproteinases after the
SIRT treatment;
3. this patient cohort demonstrated highly characteristic
molecular patterns, in contrast to all other
sub-groups.
The above summarised results are well in consensus
with statistics, observations and conclusions made by
some recently published studies. The BCMD to liver is
linked to the particularly poor outcomes: current studies
with multivariate analysis confirmed liver involvement in
BCMD as independent predictor of worse overall sur-
vival [10]. In postoperative breast cancer patients liver
metastases appear earlier than other distanced metasta-
ses [8]. Furthermore, a spontaneous dormancy of meta-
static breast cancer cells to the liver has been
demonstrated [9].
It is necessary to mention that there have been several
publications reporting favourable results with SIRT for
BCMD to the liver. Hence, Coldwell et al. reported on
34 women with unresectable breast cancer metastatic to
the liver treated with SIR-Spheres. The selection criteria
included only those patients with an ECOG performance
score of 0 or 1 with an expected survival of at least
3 months. There was a complete response in 17 % of
evaluable patients by PET imaging at 12 weeks, a partial
response in 58 %, stable disease in 20 %, and disease
progression in 5 %. 36 of 44 patients (86 %) were alive at
14 months [18]. Jakobs et al. reported in a study of 30
patients that there was a partial response in 61 % of eva-
luable patients, with stable disease or minor response in
35 %, and disease progression in 4 %. The median overall
survival was 11.7 months [19]. Cianni et al. reported on
49 patients with breast cancer liver metastases who
had failed prior chemotherapy and were treated using
SIR-Spheres microspheres. By CT and PET criteria, there
was a complete or partial response in 49 % of evaluable
patients, with stable disease in 35 % and disease progres-
sion in 16 %; technical success rate and effectiveness esti-
mated at 3 months were respectively of 98 % and 80 %;
median progression-free survival and overall survival were
9.2 and 11.6 months, respectively [20]. However, current
literature does not establish clearly, who may undergo
SIRT for breast cancer metastases to the liver.
A more focused and multidisciplinary study in the
future, with a suitable number of subject and control
patients, will be necessary to determine the possible ad-
verse effects of SIRT. The study should be designed with
proper stratification with respect to each patient’s per-
formance status, prior to the therapy, extent of meta-
static disease, and liver function.
We also know that hepatic embolisation, chemotherapy,
and radiation therapy create changes at the molecular and
cellular level, including changes involving extra-cellular
structures (i.e. the microenvironment) in, as yet, poorly
understood and potentially profound ways. This includes
stimulation of angiogenesis due to hypoxia that stimulates
angiogenesis and, therefore, tumour growth, and now, the
possibility of increased matrix metalloproteins. Large scale
studies on human subjects are limited with respect to
these phenomena. Korse et al. found a temporary elevation
in angiogenic growth factors (vascular endothelial growth
factor (VEGF), endothelin-1 (ET-1) and C-terminal
proendothelin-1 (proET-1)) in the blood in twelve patients
with well-differentiated neuroendocrine tumours and liver
metastases who had undergone hepatic artery embolisa-
tion [21]. Whereas elevation of MMPs were found to be
associated with SIRT in the study reported herein, Daniele
et al. reported that 75 patients with HCC showed statisti-
cally significant reduction in MMP-2 following treatment
with TACE [22].
There is growing evidence that tumour irradiation may
induce a variety of responses that might produce tumour
radioresistance, growth, and recurrence. While radiation-
induced DNA damage, vascular damage, and radiation–
specific fibrosis serve to favour tumour regression, certain
effects of radiation have been shown to have properties
that may result in undesirable effects. While a review of
the overall effects of radiotherapy on tumour biology
relating to the microenvironment, immune response,
resistance to hypoxia, and rapid growth is beyond the
scope of this paper, a few points are of interest.
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Cancer-associated fibroblasts (CAFs) constitute the
majority of cells within the stroma in many carcinomas.
These cells actively interact with neoplastic cells and
form a myofibroblastic microenvironment that promotes
cancer growth and survival, and supports malignancy.
They participate in the remodelling of peritumoural
stroma, which is a prerequisite of neoplastic cell inva-
sion, expansion, and metastasis [23]. CAFs are known to
secrete extra-cellular matrix proteins (such as tenascin C
and collagen I), cytokines (such as hepatocyte growth
factor, platelet-derived growth factor and chemokine lig-
and 12) and matrix remodelling enzymes (such as matrix
metalloproteinases—MMPs) [24]. Unlike myofibroblasts
that arise in response to inflammation or wound healing,
CAFs may be resistant to apoptosis and irreversibly acti-
vated by radiation. The heterogeneous nature of CAFs
varies according to tumour type and the stage of disease
progression, and may also determine whether they ex-
hibit tumour-promoting or tumour-inhibiting roles [24].
The effects on CAFs by radiotherapy have not been
studied in detail at this time. However, there is evidence
that radiotherapy may play a role in tumour survival at
the level of the extra-cellular matrix through its effect
on the transmebrane receptor, β1 integrin, and that that
β1 integrin signalling in pancreatic cancer cells is re-
quired for stromal-mediated radioprotection. By analogy,
investigation of the specific effects of radiation on the
production and action of MMPs is warranted, in view of
the findings reported herein.
Despite the fact that all 158 patients, with 15 forms of
liver malignancies, were subjected to either TACE or
SIRT, it was only in the breast cancer group that a
unique and significant experimental finding was de-
tected. The authors suggest that this emphasises the
importance of the origin of a primary tumour and its
pivotal role in determining potential treatment out-
comes. Patients should be stratified accordingly, when
the treatment algorithms are considered. Furthermore, a
multi-level diagnostic approach, including performance
of individualised molecular profiling (i.e. with appro-
priate blood tests), is essential to achieve predictable out-
comes in well stratified patients/patient cohorts.
Conclusions
The matrix metalloproteinases MMP-2 and MMP-9 are
well known prognostic factors that, when elevated, are
indicators of poor outcomes for oncologic patients. The
finding of increased MMP activity, as short- and long-
term effects in the patient group with breast cancer with
liver metastases treated with SIRT, has profound impli-
cations if it can be shown that this response was pro-
voked predominantly by the SIRT. If SIRT is to be
employed in these patients, it will be important to per-
form follow-up investigations in this patient cohort to
evaluate complementary molecular pathways that may
be co-responsible for the extended tumour growth and
for the accelerated metastatic activity observed in these
patients. After the overall picture of the molecular
events is completed, an important conclusion will be
possible to make, namely, whether SIRT might be poten-
tially considered as inappropriate for treatment of some,
if not all, hepatic metastases from breast cancer.
This may be the case, if any stratified patient cohorts
with primary breast cancer are identifiable as more re-
sistant to irradiation compared to baseline. Some indica-
tions for this kind of evaluation have been published
earlier by the authors [25]. This is to provide the main
message from the previous study supporting current
Fig. 4 “Comet Assay” analysis in breast cancer patients. The DNA
analysis has been performed ex vivo using circulating leukocytes of
a. control group versus b. breast cancer patients. Apoptotic rates
(class VI) have been correlated with decades of life in the pools of
comparison. It is evident that the apoptotic rates normally tend to
increase in the 5th and 6th decade of life. In contrast, the breast
cancer patients demonstrate much more heterogeneous image and
general tendency to decrease after the 3rd life decade. These results
have been published earlier [25]
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results and recommendations. It has been clearly dem-
onstrated (see Fig. 4a) that the controls tend to increas-
ing apoptotic rates towards progressing age. In contrast,
Fig. 4b shows an inverse tendency in breast cancer pa-
tients, with apoptotic rates generally decreasing after the
3rd decade of life. Therefore, a conclusion has been
made that at least some of the breast cancer subgroups
are more resistant against apoptosis and, consequently
may be more resistant against irradiation, if compared to
baseline. Radiation resistance is the parameter crucial
for corresponding patient stratification and should be
thoroughly investigated in patient cohorts with different
liver cancer subtypes, in order to make more optimal de-
cisions for individualised therapy approaches.
Abbreviations
BCMD, breast cancer metastatic disease; CAFs, cancer-associated fibroblasts;
CNAPs, circulating nucleic acids in plasma; CT, X-ray computed tomography;
ELISA, enzyme linked immunosorbent Assay; ET-1, endothelin-1; HCC, hepatocellular
carcinoma; MMP-2, matrix metalloproteinase 2; MMP-9, matrix metalloproteinase 9;
PET, positron emission tomography; proET-1, C-terminal proendothelin-1;
SIRT, selective internal radiation therapy; TACE, transarterial chemoembolisation;
TIMP, tissue inhibitor of metalloproteinases; VEGF, vascular endothelial growth
factor
Acknowledgements
The authors thank to the European Association for Predictive, Preventive
and Personalised Medicine (EPMA, Brussels, Belgium) for professional and
financial support of the project. The authors are greatly thankful to study
nurse Mrs. Olga Ramig (Department of Radiology, University of Bonn,
Germany) for collecting the patient data and personal supervision of the
patients over the entire time of the project. The authors would like to thank
to the Department of Radiology, University of Bonn for covering the
publication’s costs of this article.
Funding
The study funding has been performed by Department of Radiology,
University of Bonn, Germany. Two authors (KY and HS) have been awarded
with corresponding fellowship by the European Association for Predictive,
Preventive and Personalised Medicine (EPMA, Brussels, Belgium).
Availability of data and materials
The datasets supporting the conclusions of this article are included within
the article. Data on patients are available at a local database of the
Department of Radiology, Bonn, Germany, that is not open for the public.
Authors’ contributions
OG created the concept of the project, made the data interpretation and
drafted the article. KY carried out the molecular biological investigations and
participated in the preparation of the final version of the article. HS carried
out the statistical evaluation and graphical presentation of the data
collected. DT contributed to the data interpretation. HHS supervised the
project at the Department of Radiology. LB finalised the data interpretation
and paper concepts. All authors read and approved the final manuscript.
Competing interests




All the patients were informed about the purposes of the study and
consequently have signed their “consent of the patient”. All investigations
conformed to the principles outlined in the Declaration of Helsinki and were
performed with permission by the responsible Ethic’s Committee of the Medical
Faculty, Rheinische Friedrich-Wilhelms-University of Bonn. Corresponding
reference number is 283/10.
Author details
1Department of Radiology, Rheinische Friedrich-Wilhelms-University of Bonn,
Bonn, Germany. 2radiox Strahlentherapie Hamm, Hamm, Germany. 3New
York Methodist Hospital, NY Presbyterian Healthcare System, Brooklyn, NY,
USA.
Received: 29 October 2015 Accepted: 24 May 2016
References
1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW,
Comber H, et al. Cancer incidence and mortality patterns in Europe:
estimates for 40 countries in 2012. Eur J Cancer 1990. 2013;49(6):1374–403.
2. Ananthakrishnan A, Gogineni V, Saeian K. Epidemiology of primary and
secondary liver cancers. Semin Interv Radiol. 2006;23(1):47–63.
3. Kümler I, Parner VK, Tuxen MK, Skjoldbye B, Bergenfeldt M, Nelausen KM, et al.
Clinical outcome of percutaneous RF-ablation of non-operable patients with
liver metastasis from breast cancer. Radiol Med. 2015;120(6):536–41.
4. Ihnenfeld Arciénega I, Imesch P, Fink D, Dedes KJ. Prolonged complete
remission of metastatic HER2-positive breast cancer after continuous
trastuzumab treatment: a case report and review of the literature. Target
Oncol. 2015;10(2):297–301.
5. Catteau X, Simon P, Noël J-C. Myofibroblastic reaction is a common event
in metastatic disease of breast carcinoma: a descriptive study. Diagn Pathol.
2014;9:196.
6. Gámez-Pozo A, Pérez Carrión RM, Manso L, Crespo C, Mendiola C,
López-Vacas R, et al. The Long-HER study: clinical and molecular analysis of
patients with HER2+ advanced breast cancer who become long-term
survivors with trastuzumab-based therapy. PLoS One. 2014;9(10):e109611.
7. Turhan N, Esendagli G, Ozkayar O, Tunali G, Sokmensuer C, Abbasoglu O.
Co-existence of Echinococcus granulosus infection and cancer metastasis in
the liver correlates with reduced Th1 immune responses. Parasite Immunol.
2015;37(1):16–22.
8. Makita M, Sakai T, Ogiya A, Kitagawa D, Morizono H, Miyagi Y, et al. Optimal
surveillance for postoperative metastasis in breast cancer patients. Breast
Cancer. 2016;23(2):286–94. doi:10.1007/s12282-014–0571-x.
9. Wheeler SE, Clark AM, Taylor DP, Young CL, Pillai VC, Stolz DB, et al.
Spontaneous dormancy of metastatic breast cancer cells in an all human
liver microphysiologic system. Br J Cancer. 2014;111(12):2342–50.
10. Gerratana L, Fanotto V, Bonotto M, Bolzonello S, Minisini AM, Fasola G, et al.
Pattern of metastasis and outcome in patients with breast cancer. Clin Exp
Metastasis. 2015;32(2):125–33.
11. Li J, Lau GK, Chen L, Dong SS, Lan HY, Huang XR, et al. Interleukin 17A
promotes hepatocellular carcinoma metastasis via NF-kB induced matrix
metalloproteinases 2 and 9 expression. PLoS One. 2011;6(7):e21816.
doi:10.1371/journal.pone.0021816.
12. Lu Y, Zhu M, Li W, Lin B, Dong X, Chen Y, et al. Alpha fetoprotein plays a
critical role in promoting metastasis of hepatocellular carcinoma cells.
J Cell Mol Med. 2016;20(3):549–58. doi:10.1111/jcmm.12745.
13. Mehner C, Hockla A, Miller E, Ran S, Radisky DC, Radisky ES. Tumor
cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant
progression and metastasis of basal-like triple negative breast cancer.
Oncotarget. 2014;5(9):2736–49.
14. Tabariès S, Ouellet V, Hsu BE, Annis MG, Rose AA, Meunier L, et al.
Granulocytic immune infiltrates are essential for the efficient formation
of breast cancer liver metastases. Breast Cancer Res. 2015;17:45.
doi:10.1186/s13058–015–0558–3.
15. Golubnitschaja-Labudova O, Liu R, Decker C, Zhu P, Haefliger IO, Flammer J.
Altered gene expression in lymphocytes of patients with normal-tension
glaucoma. Curr Eye Res. 2000;21(5):867–76.
16. Berliner L, Lemke HU, vanSonnenberg E, Ashamalla H, Mattes MD, Dosik D,
et al. Model-guided therapy for hepatocellular carcinoma: a role for
information technology in predictive, preventive and personalized
medicine. EPMA J. 2014;5(1):16.
17. Berliner L, Lemke HU, editors. An Information Technology Framework for
Predictive, Preventive and Personalised Medicine: A Use-Case with
Hepatocellular Carcinoma. Springer; 2015. Available from: http://www.
springer.com/de/book/9783319121659. Accessed 20 Oct 2015.
Golubnitschaja et al. BMC Cancer  (2016) 16:357 Page 10 of 11
18. Coldwell DM, Kennedy AS, Nutting CW. Use of yttrium-90 microspheres in
the treatment of unresectable hepatic metastases from breast cancer.
Int J Radiat Oncol Biol Phys. 2007;69(3):800–4.
19. Jakobs TF, Hoffmann R-T, Fischer T, Stemmler H-J, Tatsch K, La Fougere C, et al.
Radioembolization in patients with hepatic metastases from breast cancer.
J Vasc Interv Radiol. 2008;19(5):683–90.
20. Cianni R, Pelle G, Urigo C, Saltarelli A, Notarianni E, Pasqualini V, et al.
Radioembolization of breast hepatic metastasis with SIR spheres loaded
with yttrium-90 (Y-90). J Clin Oncol. 2011;29(Suppl):e11577. 29.
21. Korse CM, Bonfrer JMG, Prevoo W, Baas P, Taal BG. Increase of angiogenic
growth factors after hepatic artery embolization in patients with
neuroendocrine tumours. Tumour Biol. 2011;32(4):647–52.
22. Daniele A, Divella R, Quaranta M, Mattioli V, Casamassima P, Paradiso A, et al.
Clinical and prognostic role of circulating MMP-2 and its inhibitor TIMP-2 in
HCC patients prior to and after trans-hepatic arterial chemo-embolization.
Clin Biochem. 2014;47(3):184–90.
23. Barker HE, Paget JTE, Khan AA, Harrington KJ. The tumour microenvironment
after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer.
2015;15(7):409–25.
24. Karagiannis GS, Poutahidis T, Erdman SE, Kirsch R, Riddell RH, Diamandis EP.
Cancer-associated fibroblasts drive the progression of metastasis through
both paracrine and mechanical pressure on cancer tissue. Mol Cancer Res.
2012;10(11):1403–18.
25. Yeghiazaryan K, Cebioglu M, Braun M, Kuhn W, Schild HH, Golubnitschaja O.
Noninvasive subcellular imaging in breast cancer risk assessment:
construction of diagnostic windows. Pers Med. 2011;8(3):321–30.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Golubnitschaja et al. BMC Cancer  (2016) 16:357 Page 11 of 11
